Anaconda’s ANA Catheter Studied for LVO Stroke in ANAIS Study

April 16, 2025—Anaconda Biomed, SL, announced the publication of results of the ANAIS study, which evaluated the safety and performance of the company’s ANA funnel catheter in the endovascular treatment of large vessel occlusion acute ischemic stroke.

According to the company, ANA is designed to work in conjunction with stent retrievers to arrest blood flow and reduce risk of clot fragmentation during mechanical thrombectomy.

Alejandro Tomasello, MD, et al published the study in American Journal of Neuroradiology (2025;46:502-509).

As summarized in Anaconda’s press release, ANAIS was conducted prospectively across three centers in Spain. The single-arm feasibility study was composed of 43 patients who were enrolled to receive thrombectomy within 24 hours of symptom onset, with a median National Institutes of Health Stroke Scale score of 16 at admission. Blinded outcome assessment was performed by an independent imaging core lab, and oversight was conducted by an independent data safety monitoring board.

The company reported that the primary efficacy endpoint—successful reperfusion (expanded treatment in cerebral infarction [eTICI] 2b50-3) within three passes—was achieved in 70% of patients in the intention-to-treat population and 81% in the per-protocol population. No severe device-related adverse events or symptomatic intracranial hemorrhages were observed at 24 hours.

In addition, the study allowed investigators to explore optimal device deployment strategies. When the ANA device was deployed in the internal carotid artery C2-C3 segment and continuous aspiration applied, first pass effect (eTICI 2c-3) was achieved in 83% of the cases, with successful reperfusion within three passes in 100% of this population, stated Anaconda.

“The ANAIS results represent a significant step forward in refining mechanical thrombectomy interventions,” commented Dr. Tomasello in Anaconda’s press release. “By reducing the need for multiple passes, these advancements may ultimately translate into improved neurological outcomes after stroke.”

Dr. Tomasello is Principal Investigator of the study and Head of Neurointerventional Neuroradiology at Vall d’Hebron Hospital in Barcelona, Spain.